AstraZeneca (NASDAQ:AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. Established in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the United Kingdom, the company focuses on the discovery, development, manufacture and commercialization of prescription medicines. Its research and development efforts center on four main therapy areas: oncology; cardiovascular, renal and metabolism; respiratory and immunology; and biopharmaceuticals such as vaccines.
The company’s product portfolio includes a range of treatments for cancer, heart and kidney diseases, diabetes, asthma and chronic obstructive pulmonary disease. Central to its strategy is investment in innovative science and partnerships with biotechnology firms, academic institutions and healthcare organizations. Notable products include targeted oncology therapies that inhibit tumor growth pathways, as well as inhaled and biologic treatments designed to modulate the immune response in respiratory disorders.
AstraZeneca operates in over 100 countries, with major research sites and manufacturing facilities across Europe, North America, Asia and emerging markets in Latin America, the Middle East and Africa. This geographic footprint supports global clinical trials, regulatory filings and market launches while enabling the company to address diverse patient needs and health care systems. AstraZeneca also collaborates with public health agencies and nonprofit organizations on initiatives ranging from vaccine deployment to access programs in underserved regions.
Since 2012, Pascal Soriot has served as Chief Executive Officer, guiding the company through a period of significant pipeline expansion and commercial growth. Under his leadership, AstraZeneca has secured key approvals for breakthrough therapies and has reinforced its commitment to sustainability, ethical business practices and patient-centric innovation. The company continues to pursue long-term value creation through a balanced mix of internal research, external partnerships and disciplined portfolio management.
